<a href="https://www.fiercebiotech.com/medtech/mindmaze-therapeutics-culls-program-ends-legacy-ops-relief-merger-cut-costs" hreflang="en">MindMaze Therapeutics culls program, ends legacy ops from Relief merger to cut costs </a>
MindMaze Therapeutics is streamlining its operations by selling off a pipeline program and eliminating non-neurology legacy operations from its merger with Relief Therapeutics to focus on digital treatments for neurological diseases, aiming to reduce costs by about one-third. The company plans to use the proceeds from the sale of RLF-OD032 to support its core neurology initiatives.
MindMaze Therapeutics' strategic refocus on neurology by selling non-core assets and simplifying operations signifies a clear alignment with its strengths in digital neurotherapeutics. For a professional in healthtech, this move underscores the importance of honing in on core competencies and streamlining operations to enhance adaptability and focus in a competitive medtech landscape. This could signal potential investment opportunities as MindMaze concentrates its innovation and resources on expanding its digital solutions for neurological conditions.